Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Why Achaogen Shares Are Getting Crushed On Plazomicin FDA News

Courtesy of Benzinga.

Why Achaogen Shares Are Getting Crushed On Plazomicin FDA News

Achaogen Inc (NASDAQ: AKAO) shares are tumbling Thursday after a mixed FDA panel vote on Plazomicin, its lead candidate to treat serious bacterial infections due to multidrug-resistant enterobacteriaceae.

Achaogen shares were slumping 25.3 percent to $10.98 at the time of publication. 

What Happened

The FDA’s Antimicrobial Drugs Advisory Committee voted 11-4 that the company failed to provide substantial evidence of safety and effectiveness of its plazomicin to treat bloodstream infections in patients with limited or no treatment options.

The panel voted 15-0 in favor of safety and effectiveness for treating complicated urinary tract infections. 

Why It’s Important

Plazomicin is being evaluated in two Phase 3 trials: the EPIC registration trial and CARE descriptive trial. The EPIC trial is evaluating the pipeline candidate for complicated UTIs, and is a single pivotal trial supporting a New Drug Application in the U.S. and Marketing Authorization Application, or MAA, in Europe.

The CARE trial is testing patients with serious bacterial infections.

The company submitted a NDA in October for Plazomicin for treating complicated UTIs; the FDA accepted the application in December. 

When the FDA reviews a NDA, it considers the discussions, voting pattern and recommendations of the panel. Yet the agency is not bound to go with the panel decision.

SunTrust Robinson Humphrey analyst Edward Nash said he’s optimistic for off-label usage of plazomicin for bloodstream infections, even if the indication is not present on the label.

“We believe with the options for this patient group being highly limited, along with the robust data demonstrated from the CARE study, physicians will prescribe plazomicin based on data, not label,” the analyst said.

Nash maintained a Buy rating on Achaogen with a price target lowered from $27 to $16 on the basis of lower estimated market penetration rates for bloodstream infection treatment. 

What’s Next

Plazomicin’s PDUFA action date is set for June 25. If the FDA approves the drug by the target date, Achaogen said it would launch in the U.S. soon after. 

Related Links:

Benzinga’s Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Photo by the Centers for Disease Control and Prevention via Wikimedia. 

Latest Ratings for AKAO

Date Firm Action From To
Feb 2018 Stifel Nicolaus Maintains Buy Buy
Oct 2017 Guggenheim Initiates Coverage On Buy
Oct 2017 Leerink Swann Maintains Outperform

View More Analyst Ratings for AKAO


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Price Target Reiteration FDA Top Stories Analyst Ratings Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!